GAUDIUMIVF Share Price | Gaudium IVF and Women Health Ltd Stock Analysis & Recommendation

Q: Should I buy, sell or hold Gaudium IVF and Women Health Ltd?

Based on the current information about Gaudium IVF and Women Health Ltd, it would be prudent to hold your position in the company. The fact that it is net-debt free is a positive indicator of financial health, and while the company has experienced flat results recently, it has shown a significant return on equity of 52.9%. However, the valuation appears to be quite high with a price-to-book ratio of 18.3, suggesting that the stock may be considered expensive at this time.Additionally, the company's net sales growth has been stagnant at an annual rate of 0%, which raises some concerns about its long-term growth potential. Although profits have risen by 28% over the past year, the overall flat sales performance and high valuation suggest that it may be wise to wait for a clearer growth trajectory before making any buying or selling decisions. Holding your investment for now seems to be the most sensible approach.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

2.81 lacs (94.73%) Volume

Shareholding (Mar 2026)

FII

6.70%

Held by 6 FIIs

DII

2.63%

Held by 2 DIIs

Promoter

71.29%

Which are the latest news on Gaudium IVF?

29-May-2026

No latest news for Gaudium IVF found.

Should I buy, sell or hold Gaudium IVF and Women Health Ltd?

30-May-2026

Why is Gaudium IVF and Women Health Ltd falling/rising?

30-May-2026

As of 29-May, Gaudium IVF and Women Health Ltd's stock price is at 116.40, down 0.47% and experiencing a three-day decline of 2.84%. Despite outperforming its sector today, the stock shows reduced investor participation and remains below its five-day moving average.

View full answer

Compare Gaudium IVF with Similar Stocks

Health X Platfor One Global Serv 3B Blackbio

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Strong ability to service debt as the company has a low Debt to EBITDA ratio of -999,999.00 times

Strong Long Term Fundamental Strength with an average Return on Capital Employed (ROCE) of 0%

Flat results in Mar 26

With ROCE of 90, it has a Very Expensive valuation with a 21.5 Enterprise value to Capital Employed

Mojo Parameters

Loading Valuation Snapshot...

Stock DNA

Industry

Healthcare Services

Market cap

INR 851 Cr (Micro Cap)

P/E

30.00

Industry P/E

Dividend Yield

0.00%

Debt Equity

0.27

Return on Equity

41.01%

Price to Book

18.74

Revenue and Profits:

Net Sales:

30 Cr

(Quarterly Results - Mar 2026)

Net Profit:

8 Cr

Total Returns

Total Returns (Price + Dividend)

Dividend Yield (0%)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

44.63%

6 Months

0.0%

1 Year

0.0%

2 Years

0.0%

3 Years

0.0%

4 Years

0.0%

5 Years

0.0%

Gaudium IVF for the last several years.

Risk Adjusted Returns v/s

Returns Beta

Beta has not been calculated since enough price history is not available

News & Corporate Actions

News

Gaudium IVF and Women Health Ltd is Rated Hold

Gaudium IVF and Women Health Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 29 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 30 May 2026, providing investors with the latest insights into its performance and outlook.

Read full news article

Announcements

Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015

23-May-2026 | Source : BSE

Intimation Under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015

Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

22-May-2026 | Source : BSE

Pursuant to Regulation 30 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 we wish to inform you that an Earnings Conference Call to discuss the Audited Standalone and Consolidated Financial Statements/Results of the Company for the quarter and year ended March 31 2026 is scheduled for Friday May 29 2026 at 12:00 P.M. IST.

Board Meeting Intimation for Board Meeting Intimation For Consideration And Approval Of The Audited Standalone And Consolidated Financial Statements/Results Of The Company For The Quarter And Year Ended March 31 2026.

22-May-2026 | Source : BSE

Gaudium IVF And Women Health Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/05/2026 inter alia to consider and approve the Audited Standalone and Consolidated Financial Statements/Results of the Company for the quarter and year ended March 31 2026.

Corporate Actions

BOARD MEETING

No Upcoming Board Meetings

DIVIDEND

No Dividend history available

SPLITS

No Splits history available

BONUS

No Bonus history available

RIGHTS

No Rights history available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

EBIT Growth (5y)

EBIT to Interest (avg)

14.59

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

Sales to Capital Employed (avg)

Tax Ratio

23.94%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

9.32%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

18.30

EV to EBIT

23.89

EV to EBITDA

22.28

EV to Capital Employed

21.49

EV to Sales

8.05

PEG Ratio

Dividend Yield

ROCE (Latest)

89.96%

ROE (Latest)

52.90%

Technicals key factors

Indicator

Weekly

Monthly

MACD

RSI

Bollinger Bands

KST

Dow Theory

Mildly Bullish

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Mar 2026

Shareholding Compare (%holding)

Majority shareholders

Promoters

Pledged Promoter Holdings

None

Mutual Funds

Held by 0 Schemes

FIIs

Held by 6 FIIs (6.7%)

Promoter with highest holding

Manika Khanna (70.73%)

Highest Public shareholder

Mukul Mahavir Agrawal (3.43%)

Individual Investors Holdings

14.67%

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Standalone) - Mar'26 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Mar 2026 is 56.24% vs -38.17% in Dec 2025",
        "dir": 1
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "QoQ Growth in quarter ended Mar 2026 is 143.08% vs -64.78% in Dec 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'26",
        "Dec'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "22.17",
          "val2": "14.19",
          "chgp": "56.24%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "11.27",
          "val2": "5.83",
          "chgp": "93.31%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "1.24",
          "val2": "1.12",
          "chgp": "10.71%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "7.73",
          "val2": "3.18",
          "chgp": "143.08%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "50.83%",
          "val2": "41.09%",
          "chgp": "9.74%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "half-yearly",
    "btn_text": "All Half Yearly Results",
    "alert": "No Half Yearly Results declared by Gaudium IVF"
  },
  {
    "link": "nine-monthly",
    "btn_text": "All Nine Monthly Results",
    "alert": "No Nine Monthly Results declared by Gaudium IVF"
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Standalone) - Mar'26",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Mar 2026 is 21.32% vs 12.98% in Mar 2025",
        "dir": 1
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "YoY Growth in year ended Mar 2026 is 19.65% vs 11.96% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'26",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "71.58",
          "val2": "59.00",
          "chgp": "21.32%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "34.57",
          "val2": "27.86",
          "chgp": "24.08%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "3.36",
          "val2": "1.39",
          "chgp": "141.73%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "22.29",
          "val2": "18.63",
          "chgp": "19.65%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "48.30%",
          "val2": "47.22%",
          "chgp": "1.08%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Standalone) - Mar'26 - QoQ

Mar'26

Dec'25

Change(%)

Net Sales

22.17

14.19

56.24%

Operating Profit (PBDIT) excl Other Income

11.27

5.83

93.31%

Interest

1.24

1.12

10.71%

Exceptional Items

0.00

Standalone Net Profit

7.73

3.18

143.08%

Operating Profit Margin (Excl OI)

50.83%

41.09%

9.74%

Values in Rs Cr.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Mar 2026 is 56.24% vs -38.17% in Dec 2025

Standalone Net Profit

QoQ Growth in quarter ended Mar 2026 is 143.08% vs -64.78% in Dec 2025

All Quarterly Results

Annual Results Snapshot (Standalone) - Mar'26

Mar'26

Mar'25

Change(%)

Net Sales

71.58

59.00

21.32%

Operating Profit (PBDIT) excl Other Income

34.57

27.86

24.08%

Interest

3.36

1.39

141.73%

Exceptional Items

0.00

Standalone Net Profit

22.29

18.63

19.65%

Operating Profit Margin (Excl OI)

48.30%

47.22%

1.08%

Values in Rs Cr.

Compare with Peers

Net Sales

YoY Growth in year ended Mar 2026 is 21.32% vs 12.98% in Mar 2025

Standalone Net Profit

YoY Growth in year ended Mar 2026 is 19.65% vs 11.96% in Mar 2025

All Annual Results

Company CV

About Gaudium IVF and Women Health Ltd

Gaudium IVF and Women Health Ltd

Micro Cap

Healthcare Services

No Details Available.

Company Coordinates

No Company Details Available